DelveInsight's "Metastatic Castration-Sensitive Prostate Cancer (mCSPC) - Epidemiology Forecast–2032" report delivers an in-depth understanding of the disease, historical and forecasted metastatic castration-sensitive prostate cancer (mCSPC) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2019-2032
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Disease Understanding and Treatment Algorithm
Prostate cancer is a type of malignancy that occurs in the prostate gland, which is a part of male reproductive system. Prostate cancer is the 3rd most prevalent type of cancer in the US and the fourth most common worldwide. Approximately 1 in 9 men in the US will be diagnosed with prostate cancer at some point in their lives. As per American Cancer Society, 2019, prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer.
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Epidemiology
The mCSPC epidemiology division provides insights about historical and current mCSPC patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted mCSPC epidemiology [segmented as total prevalent cases of prostate cancer, total diagnosed cases of prostate cancer, age-specific cases of prostate cancer, total diagnosed cases of prostate cancer by clinical stages, total metastatic cases of CSPC and total treated cases of metastatic CSPC in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise mCSPC Epidemiology
Estimates show that the highest cases of mCSPC in the 7MM were in the United States, followed by Japan, Germany, the United Kingdom, Italy, France, and Spain in the year 2021.
• As per DelveInsight estimates, the total prevalent population of prostate cancer in the seven major markets was 7,726,394 cases in 2021. The cases in the 7MM are expected to increase during the study period, i.e., 2019–2032.
• As per DelveInsight estimates the diagnosed cases of prostate cancer were highest in the United States. The diagnosed cases of Prostate cancer in 2021 in the US were 1,327,642 cases.
• According to the estimated, the United States accounted for 169,647, 738,038, 1,128,665, 525,093, and 131,171 for the age group ≤ 54 years, 55-64 years, 65-74 years, 75-84 years, and >84 years in 2021.
• In EU5, the total diagnosed prevalent cases of prostate cancer by clinical stages were around 656,570, 378,363, and 77,898 cases for locally advanced (Stage I–III), biochemical recurrence/progressive, and metastatic, respectively in 2021.
• Among EU5 countries, Germany had the maximum total cases of metastatic CSPC with 14,600 cases in 2021 while Spain accounted for the least number of cases. Spain accounted for 4,381 cases of metastatic CSPC in 2021.
• As per DelveInsight estimates, treated cases of metastatic CSPC in Japan were 11,094 in 2021.
Scope of the Report
• The report covers the descriptive overview of mCSPC, explaining its causes, signs and symptoms, pathophysiology, and diagnosis
• Comprehensive insight has been provided into the mCSPC epidemiology in the 7MM
• A detailed review of mCSPC market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global mCSPC market
Report Highlights
• In the coming years, mCSPC market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence mCSPC R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for mCSPC. Launch of emerging therapies will significantly impact the mCSPC market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for mCSPC
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Report Insights
• Patient Population
• Therapeutic Approaches
• mCSPC Pipeline Analysis
• mCSPC Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Report Key Strengths
• 11 Years Forecast
• 7MM Coverage
• mCSPC Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake
Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Report Assessment
• Disease Understanding
• Current Diagosis Practices and Guidelines
• Epidemiology Trends
Key Questions
• What is the disease risk, burden and regional/ethnic differences of the mCSPC?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical mCSPC patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of mCSPC in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to mCSPC?
• Out of all 7MM countries, which country would have the highest prevalent population of mCSPC during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the mCSPC market
• To understand the future market competition in the mCSPC market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for mCSPC in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for mCSPC market
• To understand the future market competition in the mCSPC market
- 1 Key Insights
- 2 Report Introduction
- 3 Executive Summary of Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- 4 Key Events
- 5 Epidemiology and Market Forecast Methodology
- 6 Disease Background and Overview
- 6.1.1 Signs and Symptoms of Prostate Cancer
- 6.1.2 Risk Factors and Causes of Prostate Cancer
- 6.1.3 Pathophysiology of Prostate Cancer
- 6.1.4 Prostate Neoplasia
- 6.1.5 Genetics of Prostate Cancer
- 7 Diagnosis of Prostate Cancer
- 7.1.1 Screening Tests for Prostate Cancer
- 7.1.2 Tests to Diagnose Prostate Cancer
- 7.1.3 Stages and Grades of Prostate Cancer
- 8 Treatment and Management of Prostate Cancer
- 8.1 Treatment Algorithm of Prostate Cancer
- 8.2 Observation or Active Surveillance
- 8.3 Surgery
- 8.3.1 Open or Laparoscopic Radical Prostatectomy
- 8.3.2 Risks of Prostate Surgery
- 8.4 Radiation Therapy
- 8.4.1 Types of Radiation Therapy
- 8.5 Hormone Therapy
- 8.5.1 Types of Hormone Therapy
- 8.6 Immunotherapy
- 8.6.1 Vaccine
- 8.6.2 Immune checkpoint inhibitors
- 8.7 Chemotherapy
- 9 American Urological Association (AUA) Guidelines for mHSPC: 2020
- 10 National Institute for health and care excellence (NICE) Recommendation Guidelines for mCSPC/mHSPC: 2022
- 11 SEOM Clinical Guidelines for mCSPC/mHNPC: 2021
- 12 Updated NCCN Guidelines for mCSPC
- 13 Epidemiology and Patient Population
- 13.1 Key Findings
- 13.2 Total Prevalent Cases of Prostate Cancer in the 7MM
- 13.3 Total Diagnosed Cases of Prostate Cancer in the 7MM
- 13.4 Total Metastatic Cases of CSPC/HSPC in the 7MM
- 13.5 Total Treated Cases of Metastatic CSPC/HSPC in the 7MM
- 13.6 Assumptions and Rationale
- 13.7 The United States
- 13.7.1 Total Diagnosed Cases of Prostate Cancer in the United States
- 13.7.2 Age-specific Cases of Prostate Cancer in the United States
- 13.7.3 Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States
- 13.7.4 Total Metastatic Cases of CSPC/HSPC in the United States
- 13.7.5 Total Treated Cases of Metastatic CSPC/HSPC in the United States
- 13.8 EU-5 Epidemiology
- 13.8.1 Total Diagnosed Prevalent cases of Prostate Cancer in EU5
- 13.8.2 Age-specific Diagnosed Prevalent Cases of Prostate Cancer in EU5
- 13.8.3 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in EU5
- 13.8.4 Total Metastatic Cases of CSPC/HSPC in EU5
- 13.8.5 Total Treated Cases of Metastatic CSPC/HSPC in EU5
- 13.9 Japan
- 13.9.1 Total Diagnosed Prevalent cases of Prostate Cancer in Japan
- 13.9.2 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan
- 13.9.3 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan
- 13.9.4 Total Metastatic Cases of CSPC/HSPC in Japan
- 13.9.5 Total Treated Cases of Metastatic CSPC/HSPC in Japan
- 14 Organizations contributing towards Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- 15 Appendix
- 15.1 Bibliography
- 16 Report Methodology
- 17 DelveInsight Capabilities
- 18 Disclaimer
- 19 About DelveInsight
- Table 1: Summary of Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Market, and Epidemiology (2019–2032)
- Table 2: Key Events
- Table 3: Genetic Changes Associated with Prostate Cancer Tumorigenesis
- Table 4: New guidelines to Consider for Metastatic Hormone-sensitive Prostate Cancer
- Table 5: Total Prevalent Cases of Prostate Cancer in the 7MM
- Table 6: Total Diagnosed Cases of Prostate Cancer in the 7MM
- Table 7: Total Diagnosed Prevalent Cases of mCSPC/mHSPC in the 7MM
- Table 8: Total Treated Cases of mHSPC/mCSPC in the 7MM
- Table 9: Total Diagnosed Cases of Prostate Cancer in the United States
- Table 10: Age-specific Cases of Prostate Cancer in the United States
- Table 11: Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the US
- Table 12: Total Diagnosed Prevalent Cases of mCSPC/mHSPC in the United States
- Table 13: Total Treated Cases of mHSPC/mCSPC in the United States
- Table 14: Total Diagnosed Prevalent Population of Prostate Cancer in EU5
- Table 15: Age-specific Diagnosed Prevalent Cases of Prostate Cancer in EU5
- Table 16: Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in EU5
- Table 17 Total Diagnosed Prevalent Cases of mCSPC/mHSPC in EU5
- Table 18: Total Treated Cases of Metastatic CSPC/HSPC in EU5
- Table 19: Total Diagnosed Prevalent cases of Prostate Cancer in Japan
- Table 20: Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan
- Table 21: Total Diagnosed Prevalent Cases of Prostate Cancer by Clinical Stages in Japan
- Table 22: Total Diagnosed Prevalent Cases of mCSPC/mHSPC in Japan
- Table 23:Total Treated Cases of Metastatic CSPC/HSPC in Japan
- Table 24: Organizations Contributing Toward the Fight Against Metastatic Hormone-Sensitive Prostate CancerFigure 1: Prostate Cancer
- Figure 2: Sign and Symptoms of Prostate Cancer
- Figure 3: Risks Factors of Prostate Cancer
- Figure 4: Pathophysiology of Prostate Cancer
- Figure 5: Progression of Prostate Cancer and the Development of mCRPC
- Figure 6: Diagnosis of Prostate Cancer
- Figure 7: Gleason Score of Prostate Cancer
- Figure 8: Localized Disease Treatment Algorithm
- Figure 9: High-risk Localized and Locally Advanced Disease Treatment Algorithm
- Figure 10: Metastatic Disease Treatment Algorithm
- Figure 11: Suggested Treatment Paradigm for Molecular Biomarkers in Advanced Prostate Cancer
- Figure 12: Total Prevalent Cases of Prostate Cancer in the 7MM
- Figure 13: Total Diagnosed Cases of Prostate Cancer in the 7MM
- Figure 14: Total Diagnosed Prevalent Cases of mCSPC/mHSPC in the 7MM
- Figure 15: Total Treated Cases of mHSPC/mCSPC in the 7MM
- Figure 16: Global Heat Map of Prostate Cancer
- Figure 17: Total Diagnosed Cases of Prostate Cancer in the United States
- Figure 18: Age-specific Cases of Prostate Cancer in the United States
- Figure 19: Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the US
- Figure 20: Total Diagnosed Prevalent Cases of mCSPC/mHSPC in the United States
- Figure 21: Total Treated Cases of mHSPC/mCSPC in the United States
- Figure 22: Total Diagnosed Prevalent Cases of Prostate Cancer in EU5
- Figure 23: Age-specific Diagnosed Prevalent Cases of Prostate Cancer in EU5
- Figure 24: Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in EU5
- Figure 25: Total Diagnosed Prevalent Cases of mCSPC/mHSPC in EU5
- Figure 26: Total Treated Cases of Metastatic CSPC/HSPC in EU5
- Figure 27: Total Diagnosed Cases of Prostate Cancer in Japan
- Figure 28: Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan
- Figure 29: Total Diagnosed Prevalent Cases of Prostate Cancer by Clinical Stages in Japan
- Figure 30: Total Diagnosed Prevalent Cases of mCSPC/mHSPC in Japan
- Figure 31: Total Treated Cases of Metastatic CSPC/HSPC in Japan
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook